Refining neutropenia risk assessment in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC) through a cell-free DNA workflow (cfDNA).

被引：2
|
作者：
Palmero, Lorenza
Mazzeo, Roberta
Buriolla, Silvia
Allegri, Lorenzo
Bortot, Lucia
Franzoni, Alessandra
Michelotti, Anna
Stefani, Elisabetta Camilla
Turra, Giulia
Zilli, Miriam
Di Nardo, Paola
Roncato, Rossana
Bonotto, Marta
Cecchin, Erika
Belletti, Barbara
Toffoli, Giuseppe
Gerratana, Lorenzo
Baldassarre, Gustavo
Damante, Giuseppe
Puglisi, Fabio
机构：
[1] Univ Udine, Dept Med Area, Udine, Italy
[2] Dept Med Oncol, IRCCS, CRO Aviano, Udine, Italy
[3] Univ Udine, Dept Med DAME, Udine, Italy
[4] Azienda Sanitaria Univ Friuli Cent ASUFC, Inst Human Genet, Udine, Italy
[5] Ctr Riferimento Oncol Aviano CRO, Dipartimento Oncol Med, IRCCS, Aviano, Italy
[6] Ctr Riferimento Oncolog Aviano CRO, Clin & Expt Pharmacol, IRCCS, Aviano, Italy
[7] Univ Hosp Udine, Dept Oncol, Udine, Italy
[8] CRO Natl Canc Inst, Aviano, Italy
[9] Ctr Riferimento Oncol Aviano CRO, Unit Mol Oncol, IRCCS, Aviano, Italy
[10] Natl Canc Inst, Expt & Clin Pharmacol, Aviano, Italy
[11] Northwestern Univ, Feinberg Sch Med, Dept Med Hematol & Oncol, Evanston, IL USA
[12] Univ Udine, Dept Med DAME, Chicago, IL USA
[13] Ctr Riferimento Oncol Aviano CRO, Unit Mol Oncol, IRCCS, I-33081 Aviano, Italy
[14] Univ Udine, Azienda Sanitaria Univ Friuli Cent ASUFC Udine, Inst Human Genet, Udine, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.1027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1027
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Cell-free DNA (cfDNA) workflow for the risk definition of dose-limiting and recurrent neutropenia in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC)
    Palmero, L.
    Mazzeo, R.
    Buriolla, S.
    Bortot, L.
    Franzoni, A.
    Michelotti, A.
    Turra, G.
    Zilli, M.
    Stefani, E. C.
    Allegri, L.
    Di Nardo, P.
    Roncato, R.
    Bonotto, M.
    Cecchin, E.
    Belletti, B.
    Toffoli, G.
    Baldassarre, G.
    Damante, G.
    Gerratana, L.
    Puglisi, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S493 - S493
  • [2] The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC)
    Eiger, Daniel
    Wagner, Marcio
    Ponde, Noam F.
    Nogueira, Melanie S.
    Buisseret, Laurence
    de Azambuja, Evandro
    ACTA ONCOLOGICA, 2020, 59 (06) : 723 - 725
  • [3] Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) treatment in metastatic lobular breast cancer (mLBC): A retrospective cohort study
    von Arx, C.
    Calabrese, A.
    Martinelli, C.
    Di Lauro, V.
    Grimaldi, V.
    Pensabene, M.
    Caputo, R.
    Cerillo, I.
    Cianniello, D.
    Buono, G.
    Verrazzo, A.
    Pacilio, C.
    Di Rella, F.
    Nuzzo, F.
    De laurentiis, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S370 - S370
  • [4] Predictors of non-receipt of first-line CDK 4/6 inhibitors (CDK4/6i) among patients with metastatic breast cancer (MBC).
    Lee, Kimberley T.
    Chiao, Elaine
    Lim, David
    Mouslim, Morgane
    Wang, Chenguang
    Mangini, Neha
    Stearns, Vered
    Smith, Karen L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Real world quality of life (QoL) in breast cancer (BC) patients treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i)
    Tavara, B. I.
    Garrido, M. L.
    Lopez, L.
    Lopez Flores, M.
    Castanon, C.
    Abella Alvarez, S.
    Medina Valdivieso, S.
    Rodriguez Sanchez, A.
    Garcia Palomo-Perez, A.
    Lopez, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S361 - S361
  • [6] UK real-world data (RWD) of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) use in metastatic breast cancer (MBC)
    Gullick, G.
    Owen, C.
    Cook, S.
    Helbrow, J.
    Squires, R.
    Reed, H. M.
    Park, S.
    Weir, E.
    Aquilina, F.
    Webber, N.
    Nye, E.
    Atkinson, C.
    Blair, C.
    Halstead, A.
    Daniels, E.
    Alves, A.
    Chew, S.
    Thomas, W.
    Spensley, S.
    Robinson, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S360 - S360
  • [7] BIOMARKERS RELATED TO SURVIVAL BENEFIT IN THE TREATMENT OF METASTATIC LUMINAL BREAST CANCER (mBC) WITH CYCLIN 4/6 INHIBITORS (CDK 4/6i) PLUS ENDOCRINE THERAPY (ET)
    Murillo, Serafin Morales
    Cudos, Ariadna Gasol
    Der-Abrain, Noemi Tuset
    Urdanibia, Izaskun
    Galindo, Alvaro Rodriguez
    Sanchez, Ana Velasco
    Villellas, Felip Vilardell
    Guzman, Douglas Sanchez
    Morales, Carles Canosa
    Olive, Jordi Mele
    Cid, Laura Arbones
    CANCER RESEARCH, 2023, 83 (05)
  • [8] Whole exome sequencing (WES) in hormone-receptor positive (HR plus ) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i).
    Wander, Seth Andrew
    Cohen, Ofir
    Johnson, Gabriela N.
    Kim, Dewey
    Luo, Flora
    Mao, Pingping
    Nayar, Utthara
    Helvie, Karla
    Marini, Lori
    Freeman, Samuel
    Getz, Gad
    Garraway, Levi A.
    Winer, Eric P.
    Lin, Nancy U.
    Wagle, Nikhil
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2-metastatic breast cancer (MBC)
    Wander, Seth A.
    Cohen, Ofir
    Gong, Xueqian
    Johnson, Gabriela N.
    Buendia-Buendia, Jorge
    Lloyd, Maxwell
    Kim, Dewey
    Luo, Flora
    Mao, Pingping
    Helvie, Karla
    Kowalski, Kailey
    Nayar, Utthara
    Parsons, Stephen
    Martinez, Ricardo
    Litchfield, Lacey
    Ye, Xiang
    Yu, Chun Ping
    Jansen, Valerie
    Garraway, Levi A.
    Winer, Eric P.
    Tolaney, Sara M.
    Lin, Nancy U.
    Buchanan, Sean
    Wagle, Nikhil
    CANCER RESEARCH, 2020, 80 (04)
  • [10] Survival according to early ctDNA dynamics in advanced breast cancer (ABC) treated with endocrine therapy (ET) and a CDK4/6 inhibitor (CDK4/6i)
    Martinez Saez, O.
    Felip Falgas, E.
    Cappelletti, M.
    Tolosa, P.
    Braso-Maristany, F.
    Sanfeliu Torres, E.
    Pascual, T.
    Chic, N.
    Vidal, M.
    Adamo, B.
    Munoz, M.
    Faull, I.
    Odegaard, J.
    Patel, G.
    McEwen, R.
    Carroll, D.
    Ciruelos, E. M.
    Generali, D. G.
    Margeli Vila, M.
    Prat, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S127 - S128
12345